FDA’s Oversight Of Clinical Trials Needs New Powers And Systems, OIG Finds
Executive Summary
The HHS Office of Inspector General is recommending that FDA seek expanded regulatory authority over clinical trials in a report that criticizes how the agency monitors studies
You may also be interested in...
Clinical Trials Face More FDA Scrutiny; DoJ Settlements Focus On Data Use
FDA is ratcheting up enforcement of clinical trial sites, conducting more inspections during the course of pivotal studies and issuing more warning letters to investigators.
Clinical Trials Face More FDA Scrutiny; DoJ Settlements Focus On Data Use
FDA is ratcheting up enforcement of clinical trial sites, conducting more inspections during the course of pivotal studies and issuing more warning letters to investigators.
NDAs Supported By Foreign Data To Be Reviewed By HHS Inspector General
HHS' Office of Inspector General will examine how FDA handles the growing number of clinical trials being conducted overseas